Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].

Terapevticheskii arkhiv - 15 Aug 2019

Klimova E A, Burnevich E Z, Chulanov V P, Gusev D A, Znoyko O O, Batskikh S N, Kizlo S N, Mamonova N A, Tarkhova E P, Krasavina E N, Samsonov M Y, Yushchuk N D

Abstract excerpt

AIM: Evaluate efficacy and safety of a combination of direct - acting antivirals narlaprevir/ritonavir with daclatasvir in patients with viral hepatitis C. MATERIALS AND METHODS: The study enrolled adult patients with HCV genotype 1b infection without demonstrated NS5A resistance - associated substitutions Y93C/H/N/S and/or L31F/M/V/I. Patients were treated with narlaprevir 200 mg QD, ritonavir 100 mg QD and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Cyclopropanes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dipeptides

Share to Imidazoles

Share to Pyrrolidines

Share to Ritonavir

Share to Sulfones

Source

Identifiers

PMID: 32598756
DOI: 10.26442/00403660.2019.08.000384

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].PMID 32598756Read ↗

Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.Semantic proximity Read ↗

[A real-world study of paritaprevir/ritonavir-ombitasvir combined with dasabuvir in the treatment of genotype 1b chronic hepatitis C].Semantic proximity Read ↗

[Real data o viral hepatitis C therapy in the Czech Republic].Semantic proximity Read ↗

Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.Semantic proximity Read ↗

[Telaprevir, PEG-IFNα-2b and ribavirin combination therapy for difficult to treat patients with genotype 2 chronic hepatitis C].Semantic proximity Read ↗

[Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir combined with ribavirin in Asian adult patients with chronic HCV genotype 1b infection and compensated cirrhosis].Semantic proximity Read ↗

[Efficacy and safety of paritaprevir/ritonavir/ombitasvir combined with dasabuvir in non-cirrhotic Asian adult patients with newly diagnosed and treated chronic HCV genotype 1b infection: a randomized, double-blind, placebo-controlled study - China data].Semantic proximity Read ↗

[Treatment of chronic hepatitis viral C: new associations].Semantic proximity Read ↗

Exploratory study of oral combination antiviral therapy for hepatitis C.Semantic proximity Read ↗

Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study.Semantic proximity Read ↗

[Efficacy of combination treatment with pegylated interferon plus ribavirin in patients chronically infected with HCV].Semantic proximity Read ↗

Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.